QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results

QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results [Accessibility Statement] Skip Navigation Delivered 6% Labs and 9% TRIAGEâ"¢ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today an ...